Alto Neuroscience (ANRO) Competitors $2.35 +0.05 (+1.96%) As of 07/3/2025 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANRO vs. AARD, TVRD, TNXP, CADL, IMMP, ACB, SLRN, CGC, TVGN, and BTMDShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Aardvark Therapeutics (AARD), Tvardi Therapeutics (TVRD), Tonix Pharmaceuticals (TNXP), Candel Therapeutics (CADL), Prima BioMed (IMMP), Aurora Cannabis (ACB), Acelyrin (SLRN), Canopy Growth (CGC), Semper Paratus Acquisition (TVGN), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Its Competitors Aardvark Therapeutics Tvardi Therapeutics Tonix Pharmaceuticals Candel Therapeutics Prima BioMed Aurora Cannabis Acelyrin Canopy Growth Semper Paratus Acquisition biote Alto Neuroscience (NYSE:ANRO) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation. Is ANRO or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Alto Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -39.35% -33.86% Aardvark Therapeutics N/A N/A N/A Does the media refer more to ANRO or AARD? In the previous week, Aardvark Therapeutics had 7 more articles in the media than Alto Neuroscience. MarketBeat recorded 13 mentions for Aardvark Therapeutics and 6 mentions for Alto Neuroscience. Aardvark Therapeutics' average media sentiment score of 0.58 beat Alto Neuroscience's score of 0.13 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ANRO or AARD? Alto Neuroscience presently has a consensus price target of $8.50, suggesting a potential upside of 262.47%. Aardvark Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 137.07%. Given Alto Neuroscience's higher possible upside, analysts plainly believe Alto Neuroscience is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, ANRO or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto NeuroscienceN/AN/A-$61.43M-$2.34-1.00Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A SummaryAardvark Therapeutics beats Alto Neuroscience on 7 of the 8 factors compared between the two stocks. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeuroscienceMED IndustryMedical SectorNYSE ExchangeMarket Cap$63.48M$2.88B$5.50B$20.64BDividend YieldN/A2.43%5.38%3.74%P/E Ratio-1.0021.5627.6028.10Price / SalesN/A172.76368.9754.27Price / CashN/A41.9536.6322.31Price / Book0.427.518.054.59Net Income-$61.43M-$55.05M$3.18B$986.06M7 Day PerformanceN/A4.61%2.82%2.79%1 Month Performance-3.89%4.89%3.70%5.41%1 Year Performance-79.82%5.84%35.41%14.62% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience2.4569 of 5 stars$2.35+2.0%$8.50+262.5%-79.8%$63.48MN/A-1.00N/AAARDAardvark TherapeuticsN/A$13.33+19.8%$31.25+134.4%N/A$241.48MN/A0.0018Analyst RevisionGap UpHigh Trading VolumeTVRDTvardi TherapeuticsN/A$25.38-1.5%$71.50+181.7%N/A$241.23M$7.14M0.0080TNXPTonix Pharmaceuticals2.6332 of 5 stars$32.79+1.3%$585.00+1,684.1%-60.3%$238.08M$10.09M-0.0250CADLCandel Therapeutics2.5011 of 5 stars$4.67-1.7%$21.00+349.7%-19.2%$237.99M$120K-3.4960Analyst RevisionIMMPPrima BioMed0.9286 of 5 stars$1.52-5.0%$7.00+360.5%-13.6%$233.66M$5.14M0.002,021ACBAurora Cannabis0.1989 of 5 stars$3.91-4.2%N/A-6.6%$229.35M$246.72M35.551,073SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CGCCanopy Growth2.8289 of 5 stars$1.19-4.0%$2.00+68.1%-80.0%$227.99M$225.65M-0.293,150TVGNSemper Paratus Acquisition4.0055 of 5 stars$1.16-3.3%$7.10+512.1%+81.5%$220.67MN/A0.003Gap DownBTMDbiote2.7058 of 5 stars$4.01+1.3%$8.00+99.5%-43.1%$216.65M$197.19M6.57194 Related Companies and Tools Related Companies Aardvark Therapeutics Competitors Tvardi Therapeutics Competitors Tonix Pharmaceuticals Competitors Candel Therapeutics Competitors Prima BioMed Competitors Aurora Cannabis Competitors Acelyrin Competitors Canopy Growth Competitors Semper Paratus Acquisition Competitors biote Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANRO) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
